Karyopharm Therapeutics Inc.’s Post

During #ASH24, Wael Gamal, PhD discusses identifying the role of endoplasmic reticulum stress in CLL T-cell dysfunction. Read more: https://lnkd.in/eJsXp-td American Society of Hematology #MoffittASH24

At #ASH24, Hammad Tashkandi, MD discussed the clinical relevance in classification methods and the prognostic implications of subgrouping within TP53-mutated myelodysplastic neoplasms as outlined by WHO and ICC. Read more: https://lnkd.in/e_SzcJXH American Society of Hematology #MoffittASH24

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

IACH News of the week 27 - October - 2024 • Here is the weekly summary of the latest in hematology Mohamad Mohty International Academy for Clinical Hematology (IACH) Controversies in Multiple Myeloma (COMy) CME Congresses https://lnkd.in/dSz-KtSy

Thanks, Richard! Today, I presented my recent results and insights on transcriptomic MYC activation in CLL. Long story short, high MYC transcriptomic activation is associated with increased interactions with the TME, suggesting MYC as an orchestrator of TME interactions and explaining why it is linked to various cellular processes. #eha #eha2024

IACH News of the week 20/October • 2024. Here is this week’s newsletter. A brief, up-to-date summary of the last week in hematology. https://lnkd.in/dSz-KtSy International Academy for Clinical Hematology (IACH) Mohamad Mohty CME Congresses Controversies in Multiple Myeloma (COMy)

Today we are working at conference EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies

Unlock the secrets of hematology staining techniques with our latest blog post on the Wright-Giemsa stain! Perfect for laboratory professionals and students, this guide provides step-by-step instructions to help you achieve precise and accurate results 🔬🎨 Dive into the details here: https://bit.ly/3ycvOvL #WrightGiemsa #LabTutorial #HardyDiagnostics

I had the honor of being part of a great team under the supervision of the esteemed Talha Badar. Our study focused on the impact of TP53 mutation on the outcome of patients with myeloproliferative neoplasms. This work was published in HemaSphere Journal, 2024;8(S1): 1855-1856, and the abstract was presented at the European Hematology Association (EHA) 2024 conference in Madrid. #Mayo_Clinic_Florida #Hematology_Oncology #MPN #TP53_Mutation #HemaSphere_Journal #EHA_2024